1. contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. 2. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 3. receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

1. contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. 2. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 3. receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

1. contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. 2. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 3. receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

1. contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator. 2. clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than covid-19 3. receipt of other investigational therapy as a part of another clinical trial. note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.